NEW YORK, May 29, 2026, 19:03 (EDT)
- Oculis said two Phase 3 trials of OCS-01 in diabetic macular edema missed their main vision goal.
- Nasdaq-listed shares closed down 23.4% at $22.70; after-hours trading was also sharply lower.
- The company said it does not now plan to seek U.S. approval for OCS-01 in DME.
Oculis Holding AG shares fell sharply on Friday after the Swiss eye-drug developer said two late-stage trials of its OCS-01 eye drops failed to meet their main goal in diabetic macular edema, a diabetes-linked swelling in the retina that can damage sight. The company said it does not currently plan to pursue a U.S. Food and Drug Administration filing for the drug in that indication.
The stock closed regular trading on Nasdaq at $22.70, down 23.4%, with volume around 2.76 million shares, far above its average volume of about 473,000. MarketWatch showed the shares at $18.35 in after-hours trading at 4:50 p.m. EDT, a further 19.2% drop from the close.
This matters now because OCS-01 had been one of the company’s lead late-stage bets. A Phase 3 trial is a large, late-stage study often used to support a drug approval request, and the primary endpoint — the main test goal — was mean change in best-corrected visual acuity, or BCVA, a standard measure of how well a patient can read an eye chart after correction. Oculis said that goal was not met in either DIAMOND-1 or DIAMOND-2.
The trial miss also landed against a stronger tape. The Nasdaq Composite rose 0.2% on Friday and the S&P 500 also added 0.2%, while the Nasdaq Biotechnology Index slipped 0.1% to 5,989.8, making Oculis’ move a company-specific break rather than a broad biotech selloff.
Oculis did report some anatomical benefit: retinal thickness, a measure of swelling, fell substantially and persistently with OCS-01 versus vehicle in both trials. But the company said the key secondary endpoint of at least a 15-letter BCVA gain was not met in either study, blunting the case for an approval filing.
Chief Executive Riad Sherif said the company was “naturally disappointed” that lower retinal thickness did not translate into improved vision at week 52. He also said Oculis would focus resources on Privosegtor in optic neuropathies and Licaminlimab in dry eye disease, calling the company’s balance sheet strong enough to keep pushing its late-stage pipeline. GlobeNewswire
Oculis said it had $278 million in cash, cash equivalents and short-term investments as of March 31, enough to fund operations into the second half of 2029. That gives management room to pivot, but it does not erase the commercial hit from shelving, at least for now, a DME filing investors had been waiting for.
The competitive backdrop is tough. DME treatment is dominated by injected anti-VEGF drugs — medicines that block vascular endothelial growth factor, a signal involved in leaky blood vessels — including Regeneron and Bayer’s Eylea and Roche’s Vabysmo. OCS-01 was being watched because an effective eye drop could have offered a less invasive option in a field still tied heavily to injections.
Analyst expectations had been running high before the readout. H.C. Wainwright raised its Oculis price target to $47 from $44 earlier this month and kept a Buy rating, while Stifel had lifted its target to $50, with both moves tied partly to trial progress and the upcoming DIAMOND data. Those calls predated Friday’s miss.
The risk is that the market now discounts more than one failed program. Oculis said the topline findings are preliminary and subject to further analysis, but if the visual-acuity miss holds and other pipeline milestones slip, investors may press the company harder on how much value remains in its late-stage portfolio despite the long cash runway.
For the week ahead, trading is likely to turn on whether Oculis gives investors a clearer read on subgroup data, the scale of any remaining OCS-01 opportunity, and how fast spending shifts toward Privosegtor and Licaminlimab. For now, the market has treated the DIAMOND result as a clean setback.
